z-logo
Premium
Glucagon‐like peptide‐1 analog, liraglutide, improves visceral sensation and gut permeability in rats
Author(s) -
Nozu Tsukasa,
Miyagishi Saori,
Kumei Shima,
Nozu Rintaro,
Takakusaki Kaoru,
Okumura Toshikatsu
Publication year - 2018
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.13808
Subject(s) - medicine , liraglutide , endocrinology , nitric oxide , visceral pain , allodynia , evans blue , hyperalgesia , intestinal permeability , pharmacology , irritable bowel syndrome , nociception , receptor , diabetes mellitus , type 2 diabetes
Abstract Background and Aim A glucagon‐like peptide‐1 analog, liraglutide, has been reported to block inflammatory somatic pain. We hypothesized that liraglutide attenuates lipopolysaccharide (LPS)‐induced and repeated water avoidance stress (WAS)‐induced visceral hypersensitivity and tested the hypothesis in rats. Methods The threshold of the visceromotor response induced by colonic balloon distention was measured to assess visceral sensation. Colonic permeability was determined in vivo by quantifying the absorbed Evans blue spectrophotometrically, which was instilled in the proximal colon for 15 min. The interleukin‐6 level in colonic mucosa was also quantified using ELISA. Results Subcutaneously injected LPS (1 mg/kg) reduced the visceromotor response threshold after 3 h. Liraglutide (300 μg/kg subcutaneously) at 15 h and 30 min before injecting LPS eliminated LPS‐induced allodynia. It also blocked the allodynia induced by repeated water avoidance stress for 1 h for three consecutive days. Neither vagotomy nor naloxone altered the antinociceptive effect of liraglutide, but N G ‐nitro‐L‐arginine methyl ester, a nitric oxide synthesis inhibitor, blocked it. LPS increased colonic permeability and the interleukin‐6 level, and the analog significantly inhibited these responses. Conclusions This study suggests that liraglutide blocked LPS‐induced visceral allodynia, which may be a nitric oxide‐dependent response, and was probably mediated by inhibiting pro‐inflammatory cytokine production and attenuating the increased gut permeability. Because the LPS‐cytokine system is considered to contribute to altered visceral sensation in irritable bowel syndrome, these results indicate the possibility that liraglutide can be useful for treating this disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here